Journal of the National Comprehensive Cancer Network : JNCCN · 2021
Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balis Frank, Green Daniel M, Anderson Clarke, Cook Shelly, Dhillon Jasreman, Gow Kenneth, Hiniker Susan, Jasty-Rao Rama, Lin Chi, Lovvorn Harold, MacEwan Iain, Martinez-Agosto Julian, Mullen Elizabeth, Murphy Erin S, Ranalli Mark, Rhee Daniel, Rokitka Denise, Tracy Elisabeth Lisa, Vern-Gross Tamara, Walsh Michael F, Walz Amy, Wickiser Jonathan, Zapala Matthew, Berardi Ryan A, Hughes Miranda
Аннотация
The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.